Treatment of Pemphigus with Positive Anti-Desmoglein Antibodies
Start oral prednisolone at 1 mg/kg/day (or 0.5-1 mg/kg/day for milder cases) combined immediately with a corticosteroid-sparing immunosuppressant—either azathioprine 2-3 mg/kg/day (if TPMT normal), mycophenolate mofetil 2-3 g/day, or rituximab (2 x 1 g infusions, 2 weeks apart). 1
First-Line Treatment Algorithm
The British Association of Dermatologists 2017 guidelines provide the definitive treatment framework for pemphigus with positive anti-desmoglein antibodies 1:
Corticosteroid Initiation
- Most cases: Begin prednisolone 1 mg/kg/day orally
- Milder disease: Use 0.5-1 mg/kg/day
- Severe disease: Consider pulsed IV methylprednisolone (10-20 mg/kg or 250-1000 mg) followed by oral prednisolone 1 mg/kg/day 1
Critical dosing adjustment: If no response within 5-7 days, increase prednisolone by 50-100% increments until disease control is achieved (defined as no new blisters and healing of existing lesions) 1. If doses exceed 1 mg/kg/day are needed, switch to pulsed IV corticosteroids rather than escalating oral doses further 1.
Mandatory Adjuvant Immunosuppression
Never use corticosteroids alone—always combine with an immunosuppressant from day one 1. Choose one of:
- Azathioprine 2-3 mg/kg/day (check TPMT levels first)
- Mycophenolate mofetil 2-3 g/day
- Rituximab (rheumatoid arthritis protocol: 1 g IV, repeat in 2 weeks)
These agents are crucial for remission maintenance, though their onset is delayed. Rituximab is increasingly recognized as highly effective, with treatment-naïve patients showing 100% response rates versus 89% in previously treated patients 2. Rituximab as first-line therapy produces better clinical and immunologic outcomes than delayed use 2.
Tapering Strategy
Once remission is achieved (no new blisters, healing of majority of lesions for 2 months), taper prednisolone gradually with a goal of ≤10 mg/day 1. Immediately assess osteoporosis risk when starting corticosteroids 1.
Second-Line Treatment
If treatment failure occurs (defined as continued disease activity despite 3 weeks of prednisolone 1.5 mg/kg/day or 12 weeks of adequate immunosuppressant dosing), switch to an alternate corticosteroid-sparing agent 1:
- Different immunosuppressant (azathioprine, mycophenolate mofetil, or rituximab—whichever not yet tried)
- Mycophenolic acid 720-1080 mg twice daily (if GI intolerance to mycophenolate mofetil)
Third-Line Options
For refractory cases, consider multidisciplinary team consultation for 1:
- Cyclophosphamide
- Intravenous immunoglobulin
- Immunoadsorption or plasmapheresis
- Methotrexate
Critical Pitfalls and Nuances
Corticosteroid-related mortality: Historical data show up to 77% of pemphigus deaths were corticosteroid-related 1. This justifies the moderate-dose approach (1 mg/kg/day) rather than older high-dose regimens (120-400 mg/day). An RCT showed no difference in disease control or relapse between low-dose (30-60 mg/day) and high-dose (120-180 mg/day) prednisolone 1.
Anti-desmoglein antibody monitoring: While positive anti-desmoglein antibodies confirm diagnosis, their persistence during remission does NOT mandate treatment escalation. Studies show 54.5% of patients in remission remain antibody-positive 3, and some maintain high titers (≥150 U/ml) for 18-70 months without relapse 4. However, persistently high anti-desmoglein 1 antibodies correlate more with relapse risk than anti-desmoglein 3 4, so taper corticosteroids more cautiously in these patients.
Age and disease duration matter: Older age and shorter disease duration predict better response to rituximab, likely due to immune senescence and less clonal diversity 5. Treatment-naïve patients achieve superior outcomes compared to those with delayed treatment 2.
Antibody dynamics post-rituximab: Anti-desmoglein 1 antibodies (particularly IgG4 subclass) decline more in pemphigus vulgaris than pemphigus foliaceus after rituximab 5. Reductions in anti-desmoglein 1 have greater prognostic value than anti-desmoglein 3 for predicting treatment response 5.